mortality/aging
|
• 66% survival at 24 weeks
|
hematopoietic system
|
• spleens are 5-fold heavier than in MRL/MpJ-Faslpr mice
|
|
• dramatically increased compared to wild-type; increased relative to Tlr9 and Fas mutants
|
|
• total levels are higher than wild-type or Faslpr mice
|
|
• lower than in Faslpr mice
|
immune system
|
• spleens are 5-fold heavier than in MRL/MpJ-Faslpr mice
|
|
• dramatically increased compared to wild-type; increased relative to Tlr9 and Fas mutants
|
|
• total levels are higher than wild-type or Faslpr mice
|
|
• lower than in Faslpr mice
|
|
• generalized lymphadenopathy
• axillary and inguinal lymph node weights are greater than in Faslpr mice (by >5-fold)
|
|
• autoantibodies such as anti-ssDNA, anti-dsDNA, anti-cardiolipin, and anti-IgG are detected, and levels are not different from Fas mutants
|
|
• interstitial lymphoid infiltration is observed at 13 weeks
• mesangial proliferation is greater than in Fas single mutants
|
homeostasis/metabolism
|
• increased more from 13 to 24 weeks than in Fas single mutants but not significantly so
|
renal/urinary system
|
• increased more from 13 to 24 weeks than in Fas single mutants but not significantly so
|
|
• interstitial lymphoid infiltration is observed at 13 weeks
• mesangial proliferation is greater than in Fas single mutants
|
|
• glomerular IgG deposits that are exclusively mesangial are more severe than in Fas single mutants
|
growth/size/body
|
• spleens are 5-fold heavier than in MRL/MpJ-Faslpr mice
|


Analysis Tools